Literature DB >> 32871004

CaNDis: a web server for investigation of causal relationships between diseases, drugs and drug targets.

Blaž Škrlj1,2, Nika Eržen1, Nada Lavrač1,2, Tanja Kunej3, Janez Konc4.   

Abstract

MOTIVATION: Causal biological interaction networks represent cellular regulatory pathways. Their fusion with other biological data enables insights into disease mechanisms and novel opportunities for drug discovery.
RESULTS: We developed Causal Network of Diseases (CaNDis), a web server for the exploration of a human causal interaction network, which we expanded with data on diseases and FDA-approved drugs, on the basis of which we constructed a disease-disease network in which the links represent the similarity between diseases. We show how CaNDis can be used to identify candidate genes with known and novel roles in disease co-occurrence and drug-drug interactions. AVAILABILITYAND IMPLEMENTATION: CaNDis is freely available to academic users at http://candis.ijs.si and http://candis.insilab.org. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
© The Author(s) 2020. Published by Oxford University Press.

Entities:  

Year:  2021        PMID: 32871004      PMCID: PMC8098028          DOI: 10.1093/bioinformatics/btaa762

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


1 Introduction

Protein–protein and protein–drug interaction networks are becoming increasingly important for drug development (Ashburn ). Such biological interactions, whether predicted or experimental, are stored in various databases (Konc ; Szklarczyk ). However, the causal relationships between the interaction partners remain relatively unexplored. A causal relationship occurs when e.g. a transcription factor increases the expression of a particular protein. Knowledge of these relationships could open up new avenues for drug development and improve our understanding of the disease processes. Tools to explore networks of causal relationships are available (Boué ; Licata ); however, the fusion of these networks with the knowledge about diseases and drugs into heterogeneous causal networks, should enable even higher understanding of diseases as well as more efficient drug discovery. In particular, such networks could be used for the study of disease co-occurrence, the simultaneous presence of two or more diseases in a patient (Hu ). We developed Causal Network of Diseases (CaNDis), a web server that enables visual exploration of a causal network of protein–protein interactions enriched with annotations on diseases and drugs. We also constructed a new disease–disease network. Here, each node is a subnetwork in the original causal network, in which all the nodes are linked to the same disease. A score is assigned to a link between a pair of diseases based on the connectivity of the two subnetworks, representing disease similarity. CaNDis is an intuitive web server based on a fast WebGL viewer (see sections ‘Software aspects and scaling’ and ‘Comparison with other tools’ in Supplementary Information). It facilitates drug discovery with respect to the identification of disease co-occurrence and drug–drug interactions at the level of drugs, genes, proteins and diseases.

2 The CaNDis web server

The CaNDis heterogeneous causal network is based on the CBN (Boué ) and SIGNOR 2.0 (Licata ) causal biological networks. It is extended with protein–RNA interactions from the PRD database (Fujimori ) and drug–gene interactions from the DGIdb database (Cotto ); gene nodes are superimposed with the gene–disease annotations from the DisGeNET database (Piñero ). Causal pathways are merged into a single network containing the interacting proteins as nodes and the causal relationships, such as increase or decrease in expression levels, as links (see section ‘The CaNDis network’ in Supplementary Information). Gene–disease annotations are added as attributes to the protein nodes and drugs and RNA are added as new nodes, which are linked to their respective target protein nodes. The obtained heterogeneous causal network contains annotations on more than 3000 complex diseases as well as on the FDA approved drugs to enable the investigation of diseases (i.e. co-occurrence of diseases) and drug–drug interactions (see section ‘Use in drug–drug interactions’ in Supplementary Information). A new disease–disease network is also developed from the heterogeneous causal network (sections ‘Disease–disease network construction’ and ‘Normalized disease–disease similarity score’ in Supplementary Information), and is available on the web server.

3 Use for identification of genes with roles in disease co-occurrence

According to epidemiological studies, patients with central nervous system (CNS) disorders, that is, Alzheimer’s disease, Parkinson’s disease and schizophrenia, are less likely to develop certain cancers (colorectal, lung and prostate), and vice versa. This inverse co-occurrence is attributed to a set of proteins, including the proteins coded by the TP53 and BCL2 genes (Behrens ; Ibáñez ; Tabarés-Seisdedos ), both of which are down-regulated in cancers and up-regulated in CNS disorders. Using ‘colorectal carcinoma’ and ‘schizophrenia’ as the inputs to the CaNDis web server, we successfully identified the TP53 tumor suppressor gene and the BCL2 anti-apoptotic gene as those in common to both the diseases (BCL2 network is shown inFig. 1). In addition, we also found proteins that have not yet been associated with either disease (Piñero ), but which could play a role in this inverse disease co-occurrence due to their interactions with the protein coded by the BCL2 gene (the list of proteins is in the caption of Fig. 1). Literature search showed that some of the identified proteins are indeed associated with both diseases. For example, the oncoprotein coded by the DDIT3 gene (Engström ) is associated with lung cancer (Li ) and upregulated in schizophrenia (Umeda-Yano ). Similarly, MAPK8 plays a role in both colorectal cancer and schizophrenia (Chandrasekaran ; He ; Szatkiewicz ). This illustrates the use of the CaNDis web server's innovative network visualization to quickly suggest candidate proteins with potential new roles in co-occurrence of diseases.
Fig. 1.

CaNDis web server causal interaction network for the BCL2 gene. Left: proteins (identified by their gene names) associated with schizophrenia (yellow circles), cancer (purple circle), both diseases (blue circles) or none of the diseases (grey circles) represented as a 3D interaction network. Drugs are black triangles. Highlighted are the BCL2 gene in the middle and its neighbors. Right: tabular view of the same interactions labeled with causal relationships (e.g. decreases). Some of the relevant neighbors of BCL2 gene are DDIT3, MAPK8, MAPK14, MAPK1, CREB1, PRKCA, CASP3 and BECN1 (all genes are available on the web server)

CaNDis web server causal interaction network for the BCL2 gene. Left: proteins (identified by their gene names) associated with schizophrenia (yellow circles), cancer (purple circle), both diseases (blue circles) or none of the diseases (grey circles) represented as a 3D interaction network. Drugs are black triangles. Highlighted are the BCL2 gene in the middle and its neighbors. Right: tabular view of the same interactions labeled with causal relationships (e.g. decreases). Some of the relevant neighbors of BCL2 gene are DDIT3, MAPK8, MAPK14, MAPK1, CREB1, PRKCA, CASP3 and BECN1 (all genes are available on the web server)

Funding

This work was supported by the Slovenian Research Agency [P2-0103, N2-0078 and N1-0142]. The first author (B.Š.) acknowledges support under the junior researcher programme. Conflict of Interest: none declared. Click here for additional data file.
  17 in total

Review 1.  Drug repositioning: identifying and developing new uses for existing drugs.

Authors:  Ted T Ashburn; Karl B Thor
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

2.  The regulation of gene expression involved in TGF-β signaling by ZNF804A, a risk gene for schizophrenia.

Authors:  Satomi Umeda-Yano; Ryota Hashimoto; Hidenaga Yamamori; Takeya Okada; Yuka Yasuda; Kazutaka Ohi; Motoyuki Fukumoto; Akira Ito; Masatoshi Takeda
Journal:  Schizophr Res       Date:  2013-02-22       Impact factor: 4.939

3.  Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation.

Authors:  Weiyang He; Qiong Wang; Jennings Xu; Xiuling Xu; Mabel T Padilla; Guosheng Ren; Xin Gou; Yong Lin
Journal:  Autophagy       Date:  2012-10-10       Impact factor: 16.016

4.  DDIT3 and KAT2A Proteins Regulate TNFRSF10A and TNFRSF10B Expression in Endoplasmic Reticulum Stress-mediated Apoptosis in Human Lung Cancer Cells.

Authors:  Tianliang Li; Ling Su; Yuanjiu Lei; Xianfang Liu; Yajing Zhang; Xiangguo Liu
Journal:  J Biol Chem       Date:  2015-03-13       Impact factor: 5.157

5.  The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.

Authors:  Katarina Engström; Helena Willén; Christina Kåbjörn-Gustafsson; Carola Andersson; Marita Olsson; Melker Göransson; Sofia Järnum; Anita Olofsson; Elisabeth Warnhammar; Pierre Aman
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

6.  SIGNOR 2.0, the SIGnaling Network Open Resource 2.0: 2019 update.

Authors:  Luana Licata; Prisca Lo Surdo; Marta Iannuccelli; Alessandro Palma; Elisa Micarelli; Livia Perfetto; Daniele Peluso; Alberto Calderone; Luisa Castagnoli; Gianni Cesareni
Journal:  Nucleic Acids Res       Date:  2020-01-08       Impact factor: 16.971

7.  Causal biological network database: a comprehensive platform of causal biological network models focused on the pulmonary and vascular systems.

Authors:  Stéphanie Boué; Marja Talikka; Jurjen Willem Westra; William Hayes; Anselmo Di Fabio; Jennifer Park; Walter K Schlage; Alain Sewer; Brett Fields; Sam Ansari; Florian Martin; Emilija Veljkovic; Renee Kenney; Manuel C Peitsch; Julia Hoeng
Journal:  Database (Oxford)       Date:  2015-04-17       Impact factor: 3.451

8.  Copy number variation in schizophrenia in Sweden.

Authors:  J P Szatkiewicz; C O'Dushlaine; G Chen; K Chambert; J L Moran; B M Neale; M Fromer; D Ruderfer; S Akterin; S E Bergen; A Kähler; P K E Magnusson; Y Kim; J J Crowley; E Rees; G Kirov; M C O'Donovan; M J Owen; J Walters; E Scolnick; P Sklar; S Purcell; C M Hultman; S A McCarroll; P F Sullivan
Journal:  Mol Psychiatry       Date:  2014-04-29       Impact factor: 15.992

9.  Molecular evidence for the inverse comorbidity between central nervous system disorders and cancers detected by transcriptomic meta-analyses.

Authors:  Kristina Ibáñez; César Boullosa; Rafael Tabarés-Seisdedos; Anaïs Baudot; Alfonso Valencia
Journal:  PLoS Genet       Date:  2014-02-20       Impact factor: 5.917

10.  DGIdb 3.0: a redesign and expansion of the drug-gene interaction database.

Authors:  Kelsy C Cotto; Alex H Wagner; Yang-Yang Feng; Susanna Kiwala; Adam C Coffman; Gregory Spies; Alex Wollam; Nicholas C Spies; Obi L Griffith; Malachi Griffith
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

View more
  3 in total

1.  Synthesis of dihydrofuran-3-one and 9,10-phenanthrenequinone hybrid molecules and biological evaluation against colon cancer cells as selective Akt kinase inhibitors.

Authors:  Jingjing Huang; Yufei Chen; Yinfeng Guo; Ming Bao; Kemiao Hong; Yuanqing Zhang; Wenhao Hu; Jinping Lei; Yongqiang Liu; Xinfang Xu
Journal:  Mol Divers       Date:  2022-06-25       Impact factor: 2.943

2.  The status of causality in biological databases: data resources and data retrieval possibilities to support logical modeling.

Authors:  Vasundra Touré; Åsmund Flobak; Anna Niarakis; Steven Vercruysse; Martin Kuiper
Journal:  Brief Bioinform       Date:  2021-07-20       Impact factor: 11.622

Review 3.  A review of causal discovery methods for molecular network analysis.

Authors:  Jack Kelly; Carlo Berzuini; Bernard Keavney; Maciej Tomaszewski; Hui Guo
Journal:  Mol Genet Genomic Med       Date:  2022-09-10       Impact factor: 2.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.